Using aberrantly expressed cell surface markers within the CD34+/CD38−/low fraction of paediatric AML patients, LSCs were found to be present at a higher frequency at diagnosis in patients who are more likely to fail treatment regimens [88]. This evidence concerns the gene CD34 and acute myeloid leukemia.